Drug Trial Radar · NCT00406419
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)
Last checked: Nov 20, 2026Latest source record: Nov 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,015
Actual
Start
Dec 27, 2006
Primary completion
Oct 6, 2009
Study completion Apr 22, 2015
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Roche Pharma AG
- First posted
- Dec 4, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in combination with methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate. Patients will be randomized to receive placebo, 200mg of intravenous ocrelizumab or 500mg of i.v. ocrelizumab on Days 1 and 15. A repeat course of i.v. treatment will be administered at Weeks 24 and 26. All patients will receive 7.5mg - 25mg/week concomitant methotrexate at a stable dose. The anticipated time on study treatment is 1-2 years. Target sample size is 1000.
Conditions
- Rheumatoid Arthritis
Interventions
MethotrexateDrug
Methotrexate tablet was administered orally at a dose 7.5-25 mg
ocrelizumabDrug
Ocrelizumab was administered via IV infusion at a dose specified in arm description
PlaceboDrug
Matching placebo to ocrelizumab was administered via IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24Time frame: Week 24
- Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 48Time frame: Week 48
- Percentage of Participants With Adverse Events (AEs)Time frame: From baseline up to 8.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Trial Information Support Line
South San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.